Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 14
2013 15
2014 17
2015 15
2016 21
2017 11
2018 22
2019 22
2020 25
2021 19
2022 11
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycaemic control in young people with type 2 diabetes. ...Adverse events occurred in 34 (64%) participants in the placebo group, 40 (77%) in the …
We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycae …
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Rosenstock J, et al. JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269. JAMA. 2019. PMID: 30418475 Free PMC article. Clinical Trial.
Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. OBJECTIVE: To evaluate the effect of linagliptin, a selective DPP-4 inhibitor, on CV o …
Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with h …
A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
Mima A. Mima A. Adv Ther. 2022 Aug;39(8):3488-3500. doi: 10.1007/s12325-022-02223-0. Epub 2022 Jun 25. Adv Ther. 2022. PMID: 35751762 Review.
Diabetic kidney disease (DKD) is one of the most important diabetic complications. DKD is also the most common cause of chronic kidney disease (CKD) and end-stage renal disease. This review focused on potential therapeutic drugs for which there is established eviden …
Diabetic kidney disease (DKD) is one of the most important diabetic complications. DKD is also the most common cause of chronic ki …
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N; CAROLINA Investigators. Rosenstock J, et al. JAMA. 2019 Sep 24;322(12):1155-1166. doi: 10.1001/jama.2019.13772. JAMA. 2019. PMID: 31536101 Free PMC article.
MAIN OUTCOMES AND MEASURES: The primary outcome was time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with the aim to establish noninferiority of linagliptin vs glimepiride, defined by the upper limit of the 2-sided 95.47% …
MAIN OUTCOMES AND MEASURES: The primary outcome was time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or non …
Linagliptin.
[No authors listed] [No authors listed] 2018 Jan 3. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Jan 3. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643871 Free Books & Documents. Review.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other oral hypoglycemic agents. Linagliptin has been linked to rare instances of clin …
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type …
Linagliptin in the Management of Type 2 Diabetes Mellitus After Kidney Transplant.
Attallah N, Yassine L. Attallah N, et al. Transplant Proc. 2021 Sep;53(7):2234-2237. doi: 10.1016/j.transproceed.2021.07.035. Epub 2021 Aug 8. Transplant Proc. 2021. PMID: 34376312
Those medications have good safety and efficacy record in the general population and in patients with mild degrees of kidney disease. METHODS: We conducted a retrospective single center analysis of safety and efficacy of linagliptin post-kidney transplantatio …
Those medications have good safety and efficacy record in the general population and in patients with mild degrees of kidney disease. …
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Kanasaki K. Kanasaki K. Clin Sci (Lond). 2018 Feb 28;132(4):489-507. doi: 10.1042/CS20180031. Print 2018 Feb 28. Clin Sci (Lond). 2018. PMID: 29491123 Free PMC article. Review.
Linagliptin is also the most potent DPP-4 inhibitor, has the highest affinity for this protein, and has the largest volume of distribution; these properties allow linagliptin to penetrate kidney tissue and tightly bind resident DPP-4. In animal models of k …
Linagliptin is also the most potent DPP-4 inhibitor, has the highest affinity for this protein, and has the largest volume of distrib …
Acute Kidney Injury Associated with Linagliptin.
Nandikanti DK, Gosmanova EO, Gosmanov AR. Nandikanti DK, et al. Case Rep Endocrinol. 2016;2016:5695641. doi: 10.1155/2016/5695641. Epub 2016 Feb 14. Case Rep Endocrinol. 2016. PMID: 26981294 Free PMC article.
About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney injury (AKI) in a patient with preexisting chronic kidney disea …
About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We rep …
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes.
Korbut AI, Taskaeva IS, Bgatova NP, Muraleva NA, Orlov NB, Dashkin MV, Khotskina AS, Zavyalov EL, Konenkov VI, Klein T, Klimontov VV. Korbut AI, et al. Int J Mol Sci. 2020 Apr 23;21(8):2987. doi: 10.3390/ijms21082987. Int J Mol Sci. 2020. PMID: 32340263 Free PMC article.
Recent data have indicated the emerging role of glomerular autophagy in diabetic kidney disease. We aimed to assess the effect of the SGLT2 inhibitor empagliflozin, the DPP4 inhibitor linagliptin, and their combination, on glomerular autophagy in a model of type 2 d …
Recent data have indicated the emerging role of glomerular autophagy in diabetic kidney disease. We aimed to assess the effect of the …
Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study.
Fayed A, Hammad AA, Abdulazim DO, Hammad H, Amin M, Elhadidy S, Salem MM, ElAzim IMA, Zsom L, Csongradi E, Soliman KM, Sharaf El Din UA. Fayed A, et al. Ren Fail. 2023 Dec;45(1):2194434. doi: 10.1080/0886022X.2023.2194434. Ren Fail. 2023. PMID: 36974638 Free PMC article. Clinical Trial.
BACKGROUND: Patients with diabetic kidney disease (DKD) are at increased risk to develop post-contrast acute kidney injury (AKI). ...The first control group received N-acetyl cysteine and saline, the 2(nd) received allopurinol, the 3(rd) group received linaglipti …
BACKGROUND: Patients with diabetic kidney disease (DKD) are at increased risk to develop post-contrast acute kidney injury (AK …
191 results